SUPERNUS PHARMACEUTICALS, INC. Tax Withholding Paid on Stock Awards
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Tax Withholding Paid on Stock Awards of $4.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $88.00K, a 91.30% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $4.55M, a 36.34% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $31.00K, a 96.86% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $811.00K, a 109.56% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $4.23M, a 55.76% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $2.71M, a 36.43% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $1.99M.
- SUPERNUS PHARMACEUTICALS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $4.64M 10-Q · filed 2026-08-03 | $4.67M derived: sum of 3 quarters · filed 2026-08-03 | $5.49M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $4.55M 10-Q · filed 2026-05-05 | $4.59M derived: sum of 2 quarters · filed 2026-05-05 | $5.40M derived: sum of 3 quarters · filed 2026-05-05 | $5.44M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $842.00K derived: sum of 2 quarters · filed 2026-03-02 | $888.00K derived: sum of 3 quarters · filed 2026-08-03 | $4.23M 10-K · filed 2026-03-02 |
| 2025-09-30 | $811.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $857.00K derived: sum of 2 quarters · filed 2026-08-03 | $4.20M 10-Q · filed 2025-11-06 | $5.18M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $3.39M 10-Q · filed 2026-08-03 | $4.37M derived: sum of 3 quarters · filed 2026-08-03 | $4.76M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $3.34M 10-Q · filed 2026-05-05 | $4.33M derived: sum of 2 quarters · filed 2026-05-05 | $4.71M derived: sum of 3 quarters · filed 2026-05-05 | $4.72M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $987.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.37M derived: sum of 2 quarters · filed 2026-03-02 | $1.38M derived: sum of 3 quarters · filed 2026-03-02 | $2.71M 10-K · filed 2026-03-02 |
| 2024-09-30 | $387.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $388.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.73M 10-Q · filed 2025-11-06 | $1.73M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.34M 10-Q · filed 2025-08-05 | $1.34M derived: sum of 3 quarters · filed 2026-03-02 | $2.31M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $1.34M 10-Q · filed 2025-05-06 | $1.34M derived: sum of 2 quarters · filed 2026-03-02 | $2.31M derived: sum of 3 quarters · filed 2026-03-02 | $2.88M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $970.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.54M derived: sum of 3 quarters · filed 2026-03-02 | $1.99M 10-K · filed 2026-03-02 |
| 2023-09-30 | $970.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.54M derived: sum of 2 quarters · filed 2024-11-04 | $1.99M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $575.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.02M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $445.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |